Please upgrade your browser.
Dr. Samadi is a board-certified urologist and an oncologist specializing in the diagnosis and treatment of urologic diseases, prostate cancer, kidney cancer...
Adding “chemical shift” techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.
That's the "dry" statement. The impact statement is that-unfortunately-for many in this country, this is more than a phrase. It's a reality that their health and their health care are in crisis. And the sooner more of us understand this, the sooner we can make a genuine effort to implement effective strategies that will address the sad state of affairs many people find themselves in when it comes to their health, and preventing and appropriately treating their diseases.
Cancer drug most prescribed under separate government cancer fund.
Anti-CD70 Immunocytokines for Exploitation of Interferon-γ-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma
Metastatic renal cell carcinoma (RCC) is an incurable disease in clear need of new therapeutic interventions. In early-phase clinical trials, the cytokine IFN-γ showed promise as a biotherapeutic for advanced RCC...
A panel of cancer experts will discuss the efficacy and safety of Tivozanib and then vote for or against approval. In most cases, the FDA follows the recommendation of the ODAC panel.
Researchers with UCLA's Institute of Urologic Oncology and department of urology have classified kidney cancer into several unique subtypes, a breakthrough that will help physicians tailor treatment to individual kidney cancer patients, moving cancer care one step closer to personalized medicine.
A live video feed from the aftermath of the explosions at today's Boston Marathon.
The AACR Annual Meeting once again highlighted the latest and most exciting discoveries in every area of cancer research and provide a unique opportunity for investigators from all over the world to meet and forge collaborations. Following are some meeting highlights specific to renal cancers.
In a study published in the journal Science Translational Medicine, the researchers detail how low doses of the drug interleukin-2 (IL-2) can alleviate chronic graft-versus-host disease (GVHD), a debilitating condition that often occurs in patients who have received a stem cell transplant. In patients with chronic GVHD, donor immune cells launch an attack on healthy tissue. IL-2 is so versatile at restoring immune system balance, the researchers found, that it may eventually become a primary treatment for chronic GVHD and may even hold promise for treating autoimmune diseases, such as rheumatoid arthritis and lupus, which result from a misguided immune system attack on otherwise healthy organs and tissues.
|Powered by NeonCRM|